- Previous close
12,712.00 - Open
12,026.00 - Bid 12,102.00 x --
- Ask 12,104.00 x --
- Day's range
11,998.00 - 12,158.00 - 52-week range
9,461.00 - 13,388.00 - Volume
473,533 - Avg. Volume
1,716,879 - Market cap (intra-day)
187.647B - Beta (5Y monthly) 0.17
- PE ratio (TTM)
38.55 - EPS (TTM)
3.14 - Earnings date 12 Nov 2024
- Forward dividend & yield 2.34 (1.84%)
- Ex-dividend date 8 Aug 2024
- 1y target est
133.44
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and BenevolentAI for drug discovery for systemic lupus erythematosus. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
www.astrazeneca.com89,900
Full-time employees
31 December
Fiscal year ends
Healthcare
Sector
Drug Manufacturers - General
Industry
Recent news: AZN.L
View morePerformance overview: AZN.L
Trailing total returns as of 10/09/2024, which may include dividends or other distributions. Benchmark is
.YTD return
1-year return
3-year return
5-year return
Compare to: AZN.L
Select to analyse similar companies using key performance metrics; select up to four stocks.
Statistics: AZN.L
View moreValuation measures
Market cap
197.07B
Enterprise value
217.22B
Trailing P/E
40.52
Forward P/E
17.83
PEG ratio (5-yr expected)
0.93
Price/sales (ttm)
5.31
Price/book (mrq)
6.55
Enterprise value/revenue
5.81
Enterprise value/EBITDA
20.25
Financial highlights
Profitability and income statement
Profit margin
13.11%
Return on assets (ttm)
7.68%
Return on equity (ttm)
16.74%
Revenue (ttm)
49.13B
Net income avi to common (ttm)
6.44B
Diluted EPS (ttm)
3.14
Balance sheet and cash flow
Total cash (mrq)
7.08B
Total debt/equity (mrq)
84.97%
Levered free cash flow (ttm)
9.82B